20 Eastbourne Terrace
About LivaNova PLCLivaNova PLC, headquartered in London, UK, is a global medical technology company formed by the merger of Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and Cyberonics Inc., a medical device company with core expertise in neuromodulation. LivaNova transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. The company employs approximately 4,600 employees worldwide. With a presence in more than 100 countries, LivaNova operates as three business franchises: Cardiac Rhythm Management, Cardiac Surgery and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (U.S.A.), respectively.
CEO: Damien McDonald
CFO: Vivid Sehgal
Please click here for LivaNova job opportunities.
117 articles with LivaNova PLC
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full-year ended December 31, 2019.
New International Consensus Statement Proposes “Difficult-to-treat Depression” as a More Clinically Useful Definition than “Treatment-Resistant Depression”
LivaNova PLC commends the recent international consensus statement published in the Journal of Affective Disorders for recommendations to identify, assess and manage depression for patients unable to achieve or sustain symptom remission despite serial treatment trials.1 While the diagnosis for these patients is often “Treatment-Resistant Depression”, the authors conclude that “Difficult-to-treat Depression” has semantic and conceptual advantages.
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its fourth quarter and full-year 2019 results on Wednesday, Feb. 26, 2020 at 1 p.m. London time (8 a.m. Eastern Standard Time).
LivaNova to Present New Data on Vagus Nerve Stimulation Therapy System at the American Epilepsy Society 2019 Annual Meeting
The first presentation is a sub-analysis of stimulation parameters that can determine the efficacy of VNS Therapy in patients with super-refractory status epilepticus
LivaNova to Restructure its Heart Valve Business Line and End Caisson Transcatheter Mitral Valve Replacement Program
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it is ending its Caisson Transcatheter Mitral Valve Replacement (TMVR) program and will undertake a restructuring of its heart valve business to improve profitability and ensure business continuity.
The discussion at the Berenberg conference is scheduled to begin at 9:45 a.m. Greenwich Mean Time on Tuesday, Dec. 3, and the discussion at the Piper Jaffray conference is scheduled to begin at 8:30 a.m.
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, honors National Epilepsy Awareness Month in the United States this November.
LivaNova PLC, a market-leading medical technology and innovation company, reported results for the quarter ended September 30, 2019.
The discussion will be available to all interested parties through a live audiocast accessible via the Investor Relations section of the LivaNova website at www.livanova.com.
LivaNova PLC, a market-leading medical technology and innovation company, will host a conference call to discuss its third quarter 2019 results on Wednesday, October 30, 2019 at 12 p.m. London time.
LivaNova PLC announced the first patient enrolled in “A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression”.
LivaNova to Present Updates on Autonomic Regulation Therapy at the 23rd Annual Scientific Meeting of the Heart Failure Society of America
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it will present a summary of implantable neuromodulation technology for patients with heart failure during the 23rd Annual Scientific Meeting of the Heart Failure Society of America, September 13 – 16, Pennsylvania Convention Center, Philadelphia.
LivaNova Receives Approval from U.S. Centers for Medicare & Medicaid Services for RECOVER Clinical Study
Study to evaluate VNS Therapy for Treatment-Resistant Depression in accordance with agency’s National Coverage Determination as part of its Coverage with Evidence Development Program
LivaNova PLC, a market-leading medical technology and innovation company, reported results for the quarter ended June 30, 2019.
The inclination of patients and surgeons toward MI procedures using thoracic catheters is increasing significantly owing to the severe complications associated with traditional open surgeries.
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today launched its innovative arterial femoral cannula, Bi-Flow, designed to prevent limb ischemia during cardiac surgery.
The versatile and compact system offers the power and simplicity to support more patients in more places
Revolutionary therapy system has treated more than 120,000 patients worldwide
LivaNova PLC announced that Stacy Enxing Seng, a Venture Partner with Lightstone Ventures and former executive at several healthcare and medical technology companies, was elected by the Company’s shareholders to join its Board of Directors during its June 18 annual general meeting.
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its second quarter 2019 results on Wednesday, July 31, 2019 at 1 p.m. London time (8 a.m. Eastern Daylight Time).